Prime Medicine's Lead Gene Editor PM577a Cleared for First-in-Human Trials in New Zealand
PRME sits 99% above its 52-week low of $1.555.
Summary
Prime Medicine has received New Zealand clearance for its Clinical Trial Application for PM577a, an investigational Prime Editor for Wilson Disease. This marks the company's first clinical authorization for an in vivo Prime Editing therapy, enabling the initiation of a global Phase 1/2 study. This is a significant de-risking event for the company's lead candidate and validates its core Prime Editing platform, which is crucial for a biotech company that recently reported a 'going concern' warning. The Phase 1/2 trial is expected to begin in the second half of 2026, with initial clinical data anticipated in 2027.
At the time of this announcement, PRME was trading at $3.09 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $570.8M. The 52-week trading range was $1.55 to $6.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.